

TABLE OF CONTENTS

ACKNOWLEDGEMENT.....	iv
CHAPTER 1.....	1
INTRODUCTION.....	1
1.1 Research Background.....	1
1.2 Research Problems.....	4
1.3 Research Objectives.....	4
1.4 Research Benefits.....	5
1.5 Authenticity Research.....	5
CHAPTER 2.....	7
LITERATUR REVIEW.....	7
2.1 Basic Theory.....	7
2.1.1 Definition of Heart Failure.....	7
2.1.2 Heart Failure Epidemiology.....	7
2.1.3 Heart Failure Pathophysiology.....	7
2.1.4 Hypertension Definition.....	8
2.1.5 Hypertension Epidemiology.....	8
2.1.6 Hypertension Etiology.....	8
2.1.7 Hypertension Pathophysiology.....	9
2.1.8 Hypertension Complications.....	10
2.1.9 Hypertension Risk Factors.....	10
2.1.10 Hypertension Diagnosis.....	13
2.1.11 Clinical Manifestations of Hypertension.....	14
2.1.12 Non-pharmacologic Therapy.....	14
2.1.13 Pharmacologic Therapy.....	16
2.1.14 Antihypertensive Combination Therapy.....	20
2.1.15 Relationship between Heart Failure and Hypertension.....	22
2.1.16 Pharmacoeconomy.....	23
2.2 Theoretical Frameworks.....	27
2.3 Conceptual Framework.....	28

CHAPTER 3	29
RESEARCH METHODS	29
3.1 Research Design.....	29
3.2 Research Period and Location.....	29
3.3 Research Population and Sample	29
3.4 Research Variables.....	30
3.6 Research Procedure.....	32
3.9 Research Flow Chart.....	35
3.10 Research Schedule	36
CHAPTER IV	37
RESULT AND DISCUSSION	37
4.1 Patient Demographic Data	37
4.1.1 Distribution of Hypertension Patients Based on Gender	37
4.1.2 Distribution of Hypertension Patients Based on Age	38
4.1.3 Distribution of Hypertension Patients Based on Length of Hospitalization	39
4.2 Therapeutic Fffectiveness	42
4.3 Cost Analysis	48
4.3.1 Direct Medical Cost.....	48
4.3.2 Cost-Effectiveness	52
CHAPTER V	55
CONCLUSSION AND RECOMENDATION	55
REFERENCES	57
ATTACHMENT	65

LIST OF TABLE

Table 1 Authenticity Research	5
Table 2 Classification of Hypertension.....	8
Table 3 Lifestyle Modification as Hypertension Control.	15
Table 4 Variable Operational Definition.....	31
Table 5 Distribution of Hypertension Patient Characteristics Based on Gender	37
Table 6 Distribution of Patient Characteristics Based on Age.....	39
Table 7 Distribution of Patient Characteristics Based on Length of Stay.....	39
Table 8 Distribution of Drug Use Other than Antihypertensive Amlodipine-Furosemide and Valsartan-Furosemide in Hypertensive Patients with Heart Failure Complications at Dr. Moewardi Hospital in 2022-2024.....	41
Table 9 Abnormal to Normal Blood Pressure Range.....	42
Table 10 Normal to Normal Blood Pressure Range.....	43
Table 11 Blood Pressure Range Not Normal to Abnormal.....	44
Table 12 Normal to Abnormal Blood Pressure Range.....	44
Table 13 Effectiveness of Antihypertensive Combination Therapy Based on Systolic and Diastolic Blood Pressure Reduction.....	47
Table 14 Comparison of Average Direct Medical Costs of Hypertensive Patients ...	48
Table 15 ACER Calculation of the Use of Antihypertensive Combination of Amlodipine-Furosemide and Valsartan-Furosemide in Hypertensive Patients at Dr. Moewardi Hospital for the Period January 2022-August 2024.	53
Table 16 ICER Calculation of the Use of Antihypertensive Combination of Amlodipine-Furosemide and Valsartan-Furosemide in Hypertensive Patients at Dr. Moewardi Hospital for the Period January 2022-August 2024.	54

LIST OF FIGURE

Figure 1 Hypertension Management Algorithm According to JNC 8	16
Figure 2 Theoretical Framework.....	27
Figure 3 Conceptual Framework.....	28

LIST OF ATTACHMENT

Attachment 1 Ethical Clearance Letter	65
Attachment 2 Declaration of Confidentiality of Medical Records	66
Attachment 3 List of Other Drugs for Hypertensive Patients with Complications of Heart Failure at Dr. Moewardi Hospital Surakarta Period July 1, 2022-August 15, 2024.....	67
Attachment 4 Blood Pressure Distribution of Patients on Admission and on Discharge from Hospital	68
Attachment 5 Cost Data of Hypertension Patients Amlodipine-Furosemide Combination at Dr. Moewardi Hospital Surakarta July 1-August 15, 2024.....	70
Attachment 6 Cost Data of Hypertension Patients Valsartan-Furosemide Combination at Dr. Moewardi Hospital Surakarta July 1-August 15, 2024.....	72
Attachment 7 Patient Data with the Highest Antihypertensive Cost of Amlodipine-Furosemide Group.....	73
Attachment 8 Patient Data with the Highest Antihypertensive Cost of Valsartan-Furosemide Group.....	73
Attachment 9 Data on Patients with the Highest Cost of Medical Devices and Other Medicines	73
Attachment 10 Patient Data with Highest Cost of Care.....	74
Attachment 11 Data of Patients with Highest Diagnostic Cost	74
Attachment 12 Cost Data of Hypertension Patients in Amlodipine-Furosemide Group	74
Attachment 13 Cost Data of Hypertension Patients in Valsartan-Furosemide Group.....	77